This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Subcutaneous, Self-Administered Methotrexate For Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard Of Care

Antares Pharma, Inc. (NASDAQ: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the treatment of adults with rheumatoid arthritis. The clinical study results were presented at the 2013 European League Against Rheumatism (EULAR) Annual Congress.

The data are from a randomized, open-label, three-way crossover study that found four hours after dose, blood concentrations of subcutaneously, self-administered methotrexate were consistently higher than concentrations of orally dosed methotrexate at all levels studied.

Oral methotrexate exposure plateaued at doses of 15 mg and higher, whereas self-administered subcutaneous methotrexate did not plateau, with exposure continuing to increase at each dose. Study investigators concluded that this resulted in higher systemic exposure than the same oral dose, which may have important clinical implications.

“These results represent a significant step forward in exploring the optimization of methotrexate, the disease modifying anti-rheumatic drug most commonly used as first-line for treatment for rheumatoid arthritis around the world,” said Michael H. Schiff, M.D., Clinical Professor of Medicine in the Rheumatology Division at the University of Colorado School Of Medicine in Denver. “Administering methotrexate subcutaneously translates to linear dose absorption which may improve the efficacy of subcutaneous methotrexate compared to oral therapy. This improved efficacy has been previously reported in the literature and observed in clinical practice. 1

The self-administration device is one component of an investigational product under review by the Food and Drug administration that combines the proprietary VIBEX™ auto-injection delivery device with an injectable version of methotrexate, the drug long regarded as the standard of care in the treatment of rheumatoid arthritis.

The study of fifty adults compared the bioavailability of methotrexate administered using the investigational self-administration device-drug combination product relative to that of the bioavailability of orally dosed methotrexate. It also assessed the safety of the first-in-class delivery system.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,992.96 +280.30 1.58%
S&P 500 2,084.49 +23.47 1.14%
NASDAQ 4,938.3950 +47.1760 0.96%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs